Kwangdong Phar (009290) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Kwangdong Phar KRW 7,101, price KRW 6,390, upside +11.1%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Kwangdong Phar for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 4,958 KRW – 10,952 KRW · fair‑value band 7,101 KRW – 8,811 KRW · the 6,390 KRW price screens below the 7,101 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Kwangdong Phar in your weekly email
Every Wednesday you see whether Kwangdong Phar is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea.
Show more
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti-inflammatory agents, neuropsychiatric solvent, digestive organ agent, antibiotic, and vitamins. The company also offers supplements for low content vitamin, mineral or vital energy substance and quasi drugs. In addition, it provides blackberry, ginger lonicerae flos, vita gold, and red ginseng gold drinks, as well as offers water, mixed drinks, tea drinks, and other drinks; and traditional health foods. The company offers its products through operation of TV, radio, and print advertising. Kwang Dong Pharmaceutical Co., Ltd. was founded in 1963 and is based in Seoul, South Korea.
Stock analysis
Kwangdong Phar (009290) currently trades at 6,390 KRW, while our model-based Fair Value estimate is 7,101 KRW, implying the stock looks roughly 10.0% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 13,989 KRW per share, and 20 of the 24 models we run sit above the 6,390 KRW price.
Bear case: the Earnings-Based group reads lowest at 3,462 KRW, and 4 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 7,101 KRW (bear) to 8,811 KRW (bull), the price of 6,390 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Kwangdong Phar reported revenue of 1.7T KRW in FY2025 versus 1.3T KRW in FY2021, a compound +5.5%/yr. Reported net income was 21.0B KRW in FY2025, compounding −3.3%/yr from FY2021.
Key figures
Market cap 317B KRW (≈ $222M) · P/S ratio 0.17 · Dividend yield 1.6% · Net margin 1.3% · Return on equity 3.3% · Return on assets (EBIT) 3.6% · Operating margin 1.8% · Revenue (TTM) 1.7T KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −3% fair-value upside, at 11%, 009290 screens cheaper than that median.
Fair Value models
Bear 7,101 KRWFair Value 7,101 KRWBull 8,811 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
Start year 2020 (pandemic). Over 10 years: +5.7% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−9.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.6%
Dividend (yield on the price)1.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 2%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −4.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 666 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score38 · Bottom 25%
Fair Value upside+11% · Above median
Profitability
Return on equity (TTM)3% · Below median
Return on assets2% · Below median
Net margin (TTM)1% · Below median
Operating margin (TTM)2% · Bottom 25%
Growth and dividend
Revenue growth9% · Above median
Dividend yield (TTM)1.6% · Below median
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Kwangdong Phar Fair Value". https://www.fairvalue-calculator.com/stock/009290
Frequently asked questions
Is Kwangdong Phar (009290) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 7,101 KRW versus a price of 6,390 KRW, about +11% upside (undervalued).
What is the fair value of 009290?
Our model-based fair value for Kwangdong Phar is 7,101 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 6,390 KRW.
What is the quality score of 009290?
Kwangdong Phar has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kwangdong Phar (009290)?
Our model-based price target is the fair value of 7,101 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 7,101 KRW, optimistic scenario 8,811 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Kwangdong Phar stock forecast for 2026?
Our models put fair value at 7,101 KRW, about +11% upside versus a price of 6,390 KRW (undervalued). Cautious scenario 7,101 KRW, optimistic scenario 8,811 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Kwangdong Phar (009290)?
Kwangdong Phar reported trailing-twelve-month revenue of about 1.7T KRW (latest available figure, as of Sep 24, 2026).
Does Kwangdong Phar pay a dividend?
Kwangdong Phar currently shows a dividend yield of about 1.56% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Kwangdong Phar (009290)?
For today's price to be fair in a discounted-cash-flow model, Kwangdong Phar would have to grow free cash flow by -2.7 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 009290 use?
Our models discount Kwangdong Phar at 11.6 %: a base by market capitalisation (micro), damped by beta 0.36, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Kwangdong Phar that is -2.7 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Kwangdong Phar (009290) delivered so far?
Over the past 5 years revenue at Kwangdong Phar grew +5.9 % a year. The price currently implies -2.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Kwangdong Phar (009290) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Kwangdong Phar (-2.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Kwangdong Phar (009290)?
The free-cash-flow yield on the price is 17.64 %: that much free cash flow Kwangdong Phar produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Kwangdong Phar (009290)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kwangdong Phar it is 7,101 KRW per share (as of Sep 24, 2026), against a price of 6,390 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Kwangdong Phar stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 009290 trades below its calculated fair value: price 6,390 KRW, fair value 7,101 KRW, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 009290?
No. The price is what the market pays today (6,390 KRW); the fair value is what the company's own numbers justify (7,101 KRW). For Kwangdong Phar the two are 710.94 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Kwangdong Phar worth?
The market values Kwangdong Phar at about 317B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 6,390 KRW; our models calculate a fair value of 7,101 KRW per share.
What do the bullish and bearish scenarios say about 009290?
Our models span a range for Kwangdong Phar: cautious scenario 7,101 KRW, base 7,101 KRW, optimistic 8,811 KRW per share (as of Sep 24, 2026, price 6,390 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kwangdong Phar (009290)?
Balance-sheet figures for Kwangdong Phar (as of Sep 24, 2026): return on equity 3.3%, debt of 0.08 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 009290 from its 52-week high?
Kwangdong Phar trades at 6,390 KRW, about 42% below its 52-week high of 10,952 KRW and 21% above the low of 5,270 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 7,101 KRW is for.
Which stocks are comparable to Kwangdong Phar?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, The Kraft Heinz Company, Foshan Haitian Flavouring and Food Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kwangdong Phar stock attractive at the current price?
The data as of Sep 24, 2026: price 6,390 KRW, calculated fair value 7,101 KRW (+11%), Quality Score 38/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 009290 calculated?
We run Kwangdong Phar through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 7,101 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Kwangdong Phar currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kwangdong Phar (009290)?
The closing price on Sep 23, 2026 was 6,390 KRW. Our model-based fair value is 7,101 KRW, about +11% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kwangdong Phar right now?
The price is below even our cautious bear case (7,101 KRW). The market is more pessimistic than our downside scenario. The price sits below our cautious bear case: the market assumes less than even our pessimistic scenario. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Kwangdong Phar
How large is the market capitalisation of Kwangdong Phar (009290)?
The market capitalisation of Kwangdong Phar is 317B KRW (≈ $222M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kwangdong Phar (009290)?
The price-to-sales ratio of Kwangdong Phar is 0.17 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Kwangdong Phar (009290)?
The dividend yield of Kwangdong Phar is 1.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kwangdong Phar (009290)?
The net margin of Kwangdong Phar is 1.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kwangdong Phar (009290)?
The return on equity (ROE) of Kwangdong Phar is 3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kwangdong Phar (009290)?
On an EBIT basis the return on assets of Kwangdong Phar is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kwangdong Phar (009290)?
The operating margin of Kwangdong Phar is 1.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kwangdong Phar (009290)?
Revenue at Kwangdong Phar is growing +8.8% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kwangdong Phar (009290)?
Earnings per share at Kwangdong Phar are growing −7.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Kwangdong Phar (009290) carry?
The net debt of Kwangdong Phar is 145B KRW (fiscal year 2025, ≈ 2.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kwangdong Phar in the live analysis
One click puts Kwangdong Phar on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
